Obesity and cancer: Mechanistic insights from transdisciplinary studies

Endocrine-Related Cancer

Volumn 22, Issue 6, 2015, Pages R365-R386

  Allott, Emma H ^a,b   Hursting, Stephen D ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Aspirin; Breast cancer; Cholesterol; Epidemiology; Insulin; Mechanisms; Metformin; Mouse models; NSAIDs; Obesity; Prostate cancer; Screening; Statins; Transdisciplinary; Weight loss

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; SEX HORMONE;

BARIATRIC SURGERY; BASAL LIKE BREAST CANCER; BREAST CANCER; CALORIC RESTRICTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER THERAPY; COMORBIDITY; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIFESTYLE; MAMMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; PROSTATE CANCER; REVIEW; WEIGHT CHANGE; WEIGHT REDUCTION; ANIMAL; BREAST NEOPLASMS; CAUSALITY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; EARLY CANCER DIAGNOSIS; FEMALE; INCIDENCE; MALE; MENOPAUSE; MOUSE; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; RISK;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALORIC RESTRICTION; CAUSALITY; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY DETECTION OF CANCER; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; LIFE STYLE; MALE; MENOPAUSE; METFORMIN; MICE; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; OBESITY; OBSERVATIONAL STUDIES AS TOPIC; PROSTATIC NEOPLASMS; RISK; WEIGHT LOSS;

EID: 84948182161     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0400     Document Type: Review

References (259)

1. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, Halverson RC, Simper SC, Hopkins PN & Hunt SC 2009 Cancer incidence and mortality after gastric bypass surgery. Obesity 17 796-802. (doi:10.1038/oby.2008.610)
2. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT & Lash TL 2011 Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. Journal of the National Cancer Institute 103 1461-1468. (doi:10.1093/jnci/djr291)
3. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, Yan W, Logan SK & Li X 2013 Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 34 2823-2832. (doi:10.1093/carcin/bgt307)
4. Allott EH, Masko EM & Freedland SJ 2013a Obesity and prostate cancer: weighing the evidence. European Urology 63 800-809. (doi:10.1016/ j.eururo.2012.11.013)
5. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG et al. 2013b Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer and Prostatic Diseases 16 391-397. (doi:10.1038/pcan.2013.48)
6. Allott EH, Tse CK, Olshan AF, Carey LA, Moorman PG & Troester MA 2014a Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Research and Treatment 147 415-421. (doi:10.1007/ s10549-014-3099-z)
7. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL & Freedland SJ 2014b Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH Database. Cancer Epidemiology, Biomarkers & Prevention 23 2349-2356. (doi:10.1158/ 1055-9965.EPI-14-0458)
8. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL & Freedland SJ 2014c Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database. BJU International 114 661-666. (doi:10.1111/ bju.12720)
9. Allott EH, Howard LE, Song HJ, Sourbeer KN, Koontz BF, Salama JK & Freedland SJ 2014d Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy. Cancer Epidemiology, Biomarkers & Prevention 23 2404-2412. (doi:10.1158/1055-9965.EPI-14-0236)
10. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP & Sherman ME 2004 Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiology, Biomarkers & Prevention 13 1558-1568.
11. American Society of Clinical Oncology 2014 The state of cancer care in America 2014: a report by the American Society of Clinical Oncology. Journal of Oncology Practice 10 119-142. (doi:10.1200/JOP.2014.001386)
12. Amy NK, Aalborg A, Lyons P & Keranen L 2006 Barriers to routine gynecological cancer screening for White and African-American obese women. International Journal of Obesity 30 147-155. (doi:10.1038/ sj.ijo.0803105)
13. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A & Nyren O 1997 Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. Journal of the National Cancer Institute 89 385-389. (doi:10.1093/jnci/89.5.385)
14. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin K IV, arkach AS & Romanyukha AA 2010 Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9 188-197. (doi:10.4161/cc.9.1.10407)
15. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Phase et al. 2009 randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. Journal of Clinical Oncology 27 4986-4993. (doi:10.1200/JCO.2009.21.9410)
16. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, Ferlay J, Miranda JJ, Romieu I, ikshit R et al. 2014 Global burden of cancer attributable to high body-mass index in 2012: a populationbased study. Lancet Oncology 16 36-46. (doi:10.1016/S1470-2045 (14)71123-4)
17. Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A & Athanasiou T 2011 Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer 117 1788-1799. (doi:10.1002/ cncr.25738)
18. de Azambuja E, Mc Caskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, ndersson M et al. 2010 The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Research and Treatment 119 145-153. (doi:10.1007/s10549-009-0512-0)
19. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M & Suissa S 2011 Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiology, Biomarkers & Prevention 20 337-344. (doi:10.1158/ 1055-9965.EPI-10-0940)
20. Azrad M & Demark-Wahnefried W 2014 The association between adiposity and breast cancer recurrence and survival: a review of the recent literature. Current Nutrition Reports 3 9-15. (doi:10.1007/s13668-013-0068-9)
21. Banegas JR, Lopez-Garcia E, Gutierrez-Fisac JL, Guallar-Castillon P & Rodriguez-Artalejo F 2003 A simple estimate of mortality attributable to excess weight in the European Union. European Journal of Clinical Nutrition 57 201-208. (doi:10.1038/sj.ejcn.1601538)
22. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr et al. 2007 Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Journal of the American Medical Association 298 2275-2280. (doi:10.1001/jama.298.19.2275)
23. Bansal D, Undela K, D'Cruz S & Schifano F 2012 Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLo S ONE 7 e46691. (doi:10.1371/journal.pone.0046691)
24. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, Mc Keown-Eyssen G, Summers RW, Rothstein R, Burke CA et al. 2003 A randomized trial of aspirin to prevent colorectal adenomas. New England Journal of Medicine 348 891-899. (doi:10.1056/ NEJMoa021735)
25. Bassett JK, Severi G, Baglietto L, Macinnis RJ, Hoang HN, Hopper JL, English DR & Giles GG 2011 Weight change and prostate cancer incidence and mortality. International Journal of Cancer 131 1711-1719. (doi:10.1002/ijc.27414)
26. Batty GD, Kivimaki M, Clarke R, Davey Smith G & Shipley MJ 2011 Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes & Control 22 311-318. (doi:10.1007/s10552-010-9691-6)
27. Befort CA, Klemp JR, Austin HL, Perri MG, Schmitz KH, Sullivan DK & Fabian CJ 2012 Outcomes of a weight loss intervention among rural breast cancer survivors. Breast Cancer Research and Treatment 132 631-639. (doi:10.1007/s10549-011-1922-3)
28. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y & Bost F 2008 The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27 3576-3586. (doi:10.1038/sj.onc.1211024)
29. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF & Bost F 2010 Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Molecular Cancer Therapeutics 9 1092-1099. (doi:10.1158/1535-7163. MCT-09-1186)
30. Bensimon L, Yin H, Suissa S, Pollak MN & Azoulay L 2014 The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiology, Biomarkers & Prevention 23 2111-2118. (doi:10.1158/ 1055-9965.EPI-14-0056)
31. Bergstrom A, Pisani P, Tenet V, Wolk A & Adami HO 2001 Overweight as an avoidable cause of cancer in Europe. International Journal of Cancer 91 421-430. (doi:10.1002/1097-0215(200002)9999:9999!::AIDIJC1053O3.0. CO;2-T)
32. Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA & Semiglazov VF 2011 More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Medical Oncology 28 1260-1263. (doi:10.1007/s12032-010-9572-6)
33. Besic N, Satej N, Ratosa I, Horvat AG, Marinko T, Gazic B & Petric R 2014 Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical and tumor characteristics. BMC Cancer 14 298. (doi:10.1186/1471-2407-14-298)
34. Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ali Sanli U & Uslu R 2014 Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. Journal of Oncology Pharmacy Practice pii 1078155214551315. (doi:10.1177/1078155214551315)
35. Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L, Shen J, Repass J, Strom S & Di Giovanni J 2011 Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prevention Research 4 2002-2014. (doi:10.1158/1940-6207.CAPR-11-0182)
36. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri- Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P et al. 2012 Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. Journal of Clinical Oncology 30 2593-2600. (doi:10.1200/JCO.2011.39.3769)
37. Bonn SE, Wiklund F, Sjolander A, Szulkin R, Stattin P, Holmberg E, Gronberg H & Balter K 2014 Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes & Control 25 933-943. (doi:10.1007/s10552-014-0393-3)
38. Bonorden MJ, Rogozina OP, Kluczny CM, Grossmann ME, Grande JP, Lokshin A & Cleary MP 2009 Cross-sectional analysis of intermittent versus chronic caloric restriction in the TRAMP mouse. Prostate 69 317-326. (doi:10.1002/pros.20878)
39. Bonorden MJ, Grossmann ME, Ewing SA, Rogozina OP, Ray A, Nkhata KJ, Liao DJ, Grande JP & Cleary MP 2012 Growth and progression of TRAMP prostate tumors in relationship to diet and obesity. Prostate Cancer 2012 article 543970. (doi:10.1155/2012/543970)
40. Bonovas S, Filioussi K, Tsavaris N & Sitaras NM 2005 Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. Journal of Clinical Oncology 23 8606-8612. (doi:10.1200/JCO.2005.02.7045)
41. Bonovas S, Filioussi K & Sitaras NM 2008 Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. International Journal of Cancer 123 899-904. (doi:10.1002/ijc.23550)
42. Borowsky AD 2011 Choosing a mouse model: experimental biology in context - the utility and limitations of mouse models of breast cancer. Cold Spring Harbor Perspectives in Biology 3 a009670. (doi:10.1101/ cshperspect.a009670)
43. Boyle JP, Thompson TJ, Gregg EW, Barker LE & Williamson DF 2010 Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics 8 29. (doi:10.1186/ 1478-7954-8-29)
44. Browning DR & Martin RM 2007 Statins and risk of cancer: a systematic review and metaanalysis. International Journal of Cancer 120 833-843. (doi:10.1002/ijc.22366)
45. Buschemeyer WC III, Klink JC, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, Cohen P, Hwang D, Johnson TL & Freedland SJ 2010 Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCIDmice. Prostate 70 1037-1043. (doi:10.1002/pros.21136)
46. Cai H, Xu Z, Xu T, Yu B & Zou Q 2014 Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes/Metabolism Research and Reviews 31 336-343. (doi:10.1002/dmrr.2582)
47. Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 348 1625-1638. (doi:10.1056/NEJMoa021423)
48. Campos-Gomez S, Valero V, Flores-Arredondo JH, Isassi-Chapa A, Rangel-Rodriguez I, Hortobagyi GN & Gonzalez-Angulo AM 2014 Breast cancer subtype and baseline characteristics from diabetic breast cancer patients are not different from nondiabetics. Breast Journal 20 434-436. (doi:10.1111/tbj.12294)
49. Canchola AJ, Anton-Culver H, Bernstein L, Clarke CA, Henderson K, Ma H, Ursin G & Horn-Ross PL 2012 Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes & Control 23 473-485. (doi:10.1007/s10552-012-9897-x)
50. Cao Y & Ma J 2011 Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prevention Research 4 486-501. (doi:10.1158/1940-6207.CAPR-10-0229)
51. Cardwell CR, Hicks BM, Hughes C & Murray LJ 2015 Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology 26 68-78. (doi:10.1097/EDE.0000000000000189)
52. Carmichael AR & Bates T 2004 Obesity and breast cancer: a review of the literature. Breast 13 85-92. (doi:10.1016/j.breast.2003.03.001)
53. Centers for Disease Control & Prevention 2011 Cancer survivors-United States, 2007. MMWR. Morbidity and Mortality Weekly Report 60 269-272.
54. Chamberlain C, Romundstad P, Vatten L, Gunnell D & Martin RM 2011 The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort. International Journal of Cancer 129 1199-1206. (doi:10.1002/ijc.25739)
55. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, Mc Tiernan A, Navarro Rosenblatt D, Thune I, Vieira R & Norat T 2014 Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Annals of Oncology 25 1901-1914. (doi:10.1093/annonc/mdu042)
56. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF & Hla T 2004 Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. PNAS 101 591-596. (doi:10.1073/pnas.2535911100)
57. Chang SL, Harshman LC & Presti JC Jr 2010 Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. Journal of Clinical Oncology 28 3951-3957. (doi:10.1200/JCO.2009.27.9406)
58. Chu DI, De Nunzio C, Gerber L, Thomas JA II, Calloway EE, Albisinni S, Senocak C, Mc Keever MG, Moreira DM, Tubaro A et al. 2011 Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer and Prostatic Diseases 14 346-353. (doi:10.1038/pcan.2011.31)
59. Cleary MP, Grande JP, Juneja SC & Maihle NJ 2004 Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutrition and Cancer 50 174-180. (doi:10.1207/s15327914nc5002-7)
60. Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI & Gammon MD 2007 Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiology, Biomarkers & Prevention 16 1803-1811. (doi:10.1158/1055-9965.EPI-06-0889)
61. Clyne M 2014 Prostate cancer: metformin - the new wonder drug? Nature Reviews. Urology 11 366. (doi:10.1038/nrurol.2014.136)
62. Colotta F, Allavena P, Sica A, Garlanda C & Mantovani A 2009 Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 1073-1081. (doi:10.1093/carcin/ bgp127)
63. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH & Buring JE 2005 Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. Journal of the American Medical Association 294 47-55. (doi:10.1001/jama.294.1.47)
64. Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH & Bush TL 2002 Body mass and stage of breast cancer at diagnosis. International Journal of Cancer 98 279-283. (doi:10.1002/ijc.10209)
65. Currie CJ, Poole CD & Gale EA 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 1766-1777. (doi:10.1007/s00125-009-1440-6)
66. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA & Morgan CL 2012 Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35 299-304. (doi:10.2337/dc11-1313)
67. Dale KM, Coleman CI, Henyan NN, Kluger J & White CM 2006 Statins and cancer risk: a meta-analysis. Journal of the American Medical Association 295 74-80. (doi:10.1001/jama.295.1.74)
68. De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA & Hursting SD 2013 The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Molecular Carcinogenesis 52 446-458. (doi:10.1002/mc.21878)
69. De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R & van Eijck CH 2013 Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. British Journal of Surgery 100 1421-1429. (doi:10.1002/bjs.9229)
70. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B & Gandini S 2010 Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 3 1451-1461. (doi:10.1158/1940-6207.CAPR-10-0157)
71. De Censi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, ofmann U et al. 2014 Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Research and Treatment 148 81-90. (doi:10.1007/s10549-014-3141-1)
72. Demierre MF, Higgins PD, Gruber SB, Hawk E & Lippman SM 2005 Statins and cancer prevention. Nature Reviews. Cancer 5 930-942. (doi:10.1038/ nrc1751)
73. Desai P, Chlebowski R, Cauley JA, Manson JE, Wu C, Martin LW, Jay A, Bock C, Cote M, etrucelli N et al. 2013 Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. Cancer Epidemiology, Biomarkers & Prevention 22 1868-1876. (doi:10.1158/1055-9965.EPI-13-0562)
74. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L & Mamounas EP 2003 Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. Journal of the National Cancer Institute 95 1467-1476. (doi:10.1093/jnci/djg060)
75. Dogan S, Hu X, Zhang Y, Maihle NJ, Grande JP & Cleary MP 2007 Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. Breast Cancer Research 9 R91. (doi:10.1186/bcr1840)
76. Doyle SL, Donohoe CL, Lysaght J & Reynolds JV 2012 Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proceedings of the Nutrition Society 71 181-189. (doi:10.1017/S002966511100320X)
77. Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L & Hursting SD 2012a Dietary energy balance modulates epithelialto- mesenchymal transition and tumor progression in murine claudinlow and basal-like mammary tumor models. Cancer Prevention Research 5 930-942. (doi:10.1158/1940-6207.CAPR-12-0034)
78. Dutton DJ & Mc Laren L 2014 The usefulness of 'corrected' body mass index vs. self-reported body mass index: comparing the population distributions, sensitivity, specificity, and predictive utility of three correction equations using Canadian population-based data. BMC Public Health 14 430. (doi:10.1186/1471-2458-14-430)
79. Eliassen AH, Colditz GA, Rosner B, Willett WC & Hankinson SE 2006 Adult weight change and risk of postmenopausal breast cancer. Journal of the American Medical Association 296 193-201. (doi:10.1001/jama. 296.2.193)
80. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV & Sawyers CL 2003 Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 223-238. (doi:10.1016/S1535-6108(03)00197-1)
81. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330 1304-1305. (doi:10.1136/bmj.38415.708634.F7)
82. Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, Phillips TA, Metheny T, Aversman S, Yeh HW et al. 2013 Favorable modulation of benign breast tissue and serum risk biomarkers is associated with O 10% weight loss in postmenopausal women. Breast Cancer Research and Treatment 142 119-132. (doi:10.1007/ s10549-013-2730-8)
83. Fagan HB, Wender R, Myers RE & Petrelli N 2011 Obesity and cancer screening according to race and gender. Journal of Obesity 2011 218250. (doi:10.1155/2011/218250)
84. Fagherazzi G, Fabre A, Boutron-Ruault MC & Clavel-Chapelon F 2010 Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. European Journal of Cancer Prevention 19 120-125. (doi:10.1097/CEJ.0b013e3283354918)
85. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD & Gaziano JM 2008 The association between statins and cancer incidence in a veterans population. Journal of the National Cancer Institute 100 134-139. (doi:10.1093/jnci/djm286)
86. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV & Gaziano JM 2011 Statins and prostate cancer diagnosis and grade in a veterans population. Journal of the National Cancer Institute 103 885-892. (doi:10.1093/jnci/djr108)
87. Field AE, Camargo CA Jr & Ogino S 2013 The merits of subtyping obesity: one size does not fit all. Journal of the American Medical Association 310 2147-2148. (doi:10.1001/jama.2013.281501)
88. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN et al. 2011 National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377 557-567. (doi:10.1016/S0140-6736(10)62037-5)
89. Ford NA, Lashinger LM, Allott EH & Hursting SD 2013a Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link. Frontiers in Oncology 3 209. (doi:10.3389/fonc.2013.00209)
90. Ford NA, Nunez NP, Holcomb VB & Hursting SD 2013b IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression. Endocrine-Related Cancer 20 39-51. (doi:10.1530/ ERC-12-0329)
91. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F & Nicolucci A 2013 Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLo S ONE 8 e71583. (doi:10.1371/journal. pone.0071583)
92. Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B & Aronson WJ 2004 Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. Journal of Urology 172 520-524. (doi:10.1097/01.ju. 0000135302.58378.ae)
93. Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI & Partin AW 2005 Obesity and capsular incision at the time of open retropubic radical prostatectomy. Journal of Urology 174 1798-1801. (doi:10.1097/01.ju.0000177077.53037.72)
94. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ & Terris MK 2006 Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. Journal of Urology 175 500-504. (doi:10.1016/S0022-5347(05)00162-X)
95. Friedman AM, Hemler JR, Rossetti E, Clemow LP & Ferrante JM 2012 Obese women's barriers to mammography and pap smear: the possible role of personality. Obesity 20 1611-1617. (doi:10.1038/oby.2012.50)
96. Fryar CD, Chen TC & Li X 2012 Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010. NCHS Data Brief 1-8.
97. Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, hen J et al. 2014 Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptorpositive breast cancer. Journal of the National Cancer Institute 106 dju158. (doi:10.1093/jnci/dju158)
98. Galet C, Gray A, Said JW, Castor B, Wan J, Beltran PJ, Calzone FJ, Elashoff D, Cohen P & Aronson WJ 2013 Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts. International Journal of Molecular Sciences 14 13782-13795. (doi:10.3390/ijms140713782)
99. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, De Censi A & Szabo E 2014 Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prevention Research 7 867-885. (doi:10.1158/ 1940-6207.CAPR-13-0424)
100. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W & Bernstein JL 2011 Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Research and Treatment 130 587-597. (doi:10.1007/s10549-011-1616-x)
101. Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS & Maclean PS 2012 Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Research 72 6490-6501. (doi:10.1158/0008-5472.CAN-12-1653)
102. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG & Yee D 2010 Diabetes and cancer: a consensus report. Diabetes Care 33 1674-1685. (doi:10.2337/ dc10-0666)
103. Goodwin PJ & Pritchard KI 2010 Obesity and hormone therapy in breast cancer: an unfinished puzzle. Journal of Clinical Oncology 28 3405-3407. (doi:10.1200/JCO.2010.29.5113)
104. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK & Hood N 2012 Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. Journal of Clinical Oncology 30 164-171. (doi:10.1200/JCO.2011.36.2723)
105. Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, Blackburn GL, Findlay B, Gralow JR, ukherjee S et al. 2014 Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. Journal of Clinical Oncology 32 2231-2239. (doi:10.1200/JCO.2013.53.1517)
106. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL et al. 2012 Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology 30 1553-1561. (doi:10.1200/JCO.2011.39.9436)
107. Grubb RL III, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD et al. 2009 Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiology, Biomarkers & Prevention 18 748-751. (doi:10.1158/1055-9965.EPI-08-0938)
108. Gu Q P-RR, Burt VL & Kit BK 2014 Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief 1-8.
109. Gupta S, Adhami VM, Subbarayan M, Mac Lennan GT, Lewin JS, Hafeli UO, Fu P & Mukhtar H 2004 Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Research 64 3334-3343. (doi:10.1158/0008-5472.CAN-03-2422)
110. Hakkak R, Mac Leod S, Shaaf S, Holley AW, Simpson P, Fuchs G, Jo CH, Kieber-Emmons T & Korourian S 2007 Obesity increases the incidence of 7, 12-dimethylbenz(a)anthracene-induced mammary tumors in an ovariectomized Zucker rat model. International Journal of Oncology 30 557-563. (doi:10.3892/ijo.30.3.557)
111. Hardie DG & Alessi DR 2013 LKB1 and AMPK and the cancer-metabolism link - ten years after. BMCBiology 11 36. (doi:10.1186/1741-7007-11-36)
112. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR & Sellers TA 2005 Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiology, Biomarkers & Prevention 14 656-661. (doi:10.1158/1055-9965.EPI-04-0001)
113. Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG et al. 2011 The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. International Journal of Obesity 35 714-727. (doi:10.1038/ijo. 2010.171)
114. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH & Yeung SC 2012 Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2C breast cancer. Annals of Oncology 23 1771-1780. (doi:10.1093/annonc/mdr534)
115. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, handrasekharan S et al. 2007 Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology 8 R76. (doi:10.1186/gb-2007-8-5-r76)
116. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM et al. 2002 Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Research 62 5405-5407.
117. Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L & Canadian Cancer Registries Epidemiology Research Group 2012 Dietary cholesterol intake and cancer. Annals of Oncology 23 491-500. (doi:10.1093/annonc/mdr155)
118. Hu MB, Liu SH, Jiang HW, Bai PD & Ding Q 2014 Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29, 464 patients. PLo S ONE 9 e106677. (doi:10.1371/journal.pone.0106677)
119. Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, Vogel VG & Weissfeld JL 2008 Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 17 680-687. (doi:10.1158/ 1055-9965.EPI-07-2739)
120. Hursting SD, Smith SM, Lashinger LM, Harvey AE & Perkins SN 2010 Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 31 83-89. (doi:10.1093/carcin/bgp280)
121. Ioannides SJ, Barlow PL, Elwood JM & Porter D 2014 Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptorpositive breast cancer: a systematic review. Breast Cancer Research and Treatment 147 237-248. (doi:10.1007/s10549-014-3091-7)
122. Irwin ML 2014 Weight loss interventions and breast cancer survival: the time is now. Journal of Clinical Oncology 32 2197-2199. (doi:10.1200/ JCO.2014.56.4583)
123. Jacobs EJ, Stevens VL, Newton CC & Gapstur SM 2012 Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes & Control 23 1289-1296. (doi:10.1007/s10552-012-0006-y)
124. Jakovljevic J, Touillaud MS, Bondy ML, Singletary SE, Pillow PC & Chang S 2002 Dietary intake of selected fatty acids, cholesterol and carotenoids and estrogen receptor status in premenopausal breast cancer patients. Breast Cancer Research and Treatment 75 5-14. (doi:10.1023/ A:1016588629495)
125. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
126. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN & Giordano SH 2013 Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Annals of Oncology 24 2506-2514. (doi:10.1093/annonc/mdt224)
127. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC & Platz EA 2011 Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prevention Research 4 544-551. (doi:10.1158/ 1940-6207.CAPR-10-0257)
128. Kasper JS & Giovannucci E 2006 A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 15 2056-2062. (doi:10.1158/1055-9965.EPI-06-0410)
129. Kasper JS, Liu Y & Giovannucci E 2009 Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. International Journal of Cancer 124 1398-1403. (doi:10.1002/ijc.24044)
130. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE & Bergstralh EJ 2013 Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urologic Oncology 32 43e1-43e7. (doi:10.1016/j.urolonc. 2013.05.005)
131. Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R & Buist DS 2008 Obesity, mammography use and accuracy, and advanced breast cancer risk. Journal of the National Cancer Institute 100 1724-1733. (doi:10.1093/jnci/djn388)
132. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL & Freedland SJ 2011 Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU International 110 492-498. (doi:10.1111/j.1464-410X.2011.10754.x)
133. Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE et al. 2007 COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncology 8 912-920. (doi:10.1016/S1470-2045(07)70280-2)
134. Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH & Samet JM 2011 Total cholesterol and cancer risk in a large prospective study in Korea. Journal of Clinical Oncology 29 1592-1598. (doi:10.1200/JCO.2010.31.5200)
135. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, ohen P et al. 2008 Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Research 68 3066-3073. (doi:10.1158/0008-5472.CAN-07-5616)
136. Kowall B, Stang A, Rathmann W & Kostev K 2015 No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiology and Drug Safety 24 865-874. (doi:10.1002/ pds.3823)
137. Krycer JR & Brown AJ 2013 Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochimica et Biophysica Acta 1835 219-229. (doi:10.1016/j.bbcan.2013.01.002)
138. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH & Esserman LJ 2008 Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiology, Biomarkers & Prevention 17 1028-1033. (doi:10.1158/1055-9965.EPI-07-0726)
139. Kuoppala J, Lamminpaa A & Pukkala E 2008 Statins and cancer: a systematic review and meta-analysis. European Journal of Cancer 44 2122-2132. (doi:10.1016/j.ejca.2008.06.025)
140. Kwan ML, Habel LA, Flick ED, Quesenberry CP & Caan B 2008 Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Research and Treatment 109 573-579. (doi:10.1007/s10549-007-9683-8)
141. Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 121 856-862. (doi:10.1002/ijc.22717)
142. Lashinger LM, Ford NA & Hursting SD 2014a Interacting inflammatory and growth factor signals underlie the obesity-cancer link. Journal of Nutrition 144 109-113. (doi:10.3945/jn.113.178533)
143. Lashinger LM, Rossi EL & Hursting SD 2014b Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation. Clinical Pharmacology and Therapeutics 96 458-463. (doi:10.1038/clpt.2014.136)
144. Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, Falzarano SM, Magi-Galluzzi C, Klein EA & Ting AH 2013 Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Research 73 1211-1218. (doi:10.1158/0008-5472. CAN-12-3128)
145. Lega IC, Shah PS, Margel D, Beyene J, Rochon PA & Lipscombe LL 2014 The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiology, Biomarkers & Prevention 23 1974-1984. (doi:10.1158/1055-9965.EPI-14-0327)
146. Li C, Ford ES, Mc Guire LC & Mokdad AH 2007 Increasing trends in waist circumference and abdominal obesity among US adults. Obesity 15 216-224. (doi:10.1038/oby.2007.505)
147. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN & Brewster AM 2008 Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. Journal of Clinical Oncology 26 4072-4077. (doi:10.1200/JCO.2007.14.4527)
148. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF & Hla T 2001 Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Journal of Biological Chemistry 276 18563-18569. (doi:10.1074/jbc.M010787200)
149. Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, Gao Y, Qin X & Li S 2014 Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Medicine 12 55. (doi:10.1186/1741-7015-12-55)
150. Liu J, Ramakrishnan SK, Khuder SS, Kaw MK, Muturi HT, Lester SG, Lee SJ, Fedorova LV, Kim AJ, Mohamed IE et al. 2015 High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene. Molecular Metabolism 4 186-198. (doi:10.1016/ j.molmet.2014.12.011)
151. Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP & Frank PG 2010 AWestern-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. American Journal of Pathology 177 3180-3191. (doi:10.2353/ajpath.2010.100568)
152. Lyman GH & Sparreboom A 2013 Chemotherapy dosing in overweight and obese patients with cancer. Nature Reviews. Clinical Oncology 10 451-459. (doi:10.1038/nrclinonc.2013.108)
153. Lyman GH, Dale DC & Crawford J 2003 Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. Journal of Clinical Oncology 21 4524-4531. (doi:10.1200/JCO.2003.05.002)
154. Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC & Schedin P 2011 Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nature Medicine 17 1109-1115. (doi:10.1038/ nm.2416)
155. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M & Stampfer MJ 2008 Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology 9 1039-1047. (doi:10.1016/S1470-2045(08)70235-3)
156. Mac Innis RJ & English DR 2006 Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes & Control 17 989-1003. (doi:10.1007/s10552-006-0049-z)
157. Makari-Judson G, Braun B, Jerry DJ & Mertens WC 2014 Weight gain following breast cancer diagnosis: Implication and proposed mechanisms. World Journal of Clinical Oncology 5 272-282. (doi:10.5306/wjco.v5.i3.272)
158. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC & Fleshner N 2013 Metformin use and all-cause and prostate cancerspecific mortality among men with diabetes. Journal of Clinical Oncology 31 3069-3075. (doi:10.1200/JCO.2012.46.7043)
159. Martin RM, Vatten L, Gunnell D, Romundstad P & Nilsen TI 2009 Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes & Control 20 1181-1192. (doi:10.1007/s10552-009-9319-x)
160. Maruthur NM, Bolen S, Brancati FL & Clark JM 2009 Obesity and mammography: a systematic review and meta-analysis. Journal of General Internal Medicine 24 665-677. (doi:10.1007/s11606-009-0939-3)
161. Mass AY, Agalliu I, Laze J & Lepor H 2012 Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. Journal of Urology 188 786-791. (doi:10.1016/j.juro.2012.05.011)
162. Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA & Adamovich E 2007 Obesity is not predictive of overall survival following permanent prostate brachytherapy. American Journal of Clinical Oncology 30 588-596. (doi:10.1097/COC.0b013e318068b506)
163. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE & Nurses' Health S 2003 Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26 1752-1758. (doi:10.2337/diacare.26.6.1752)
164. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT et al. 2008 Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment 109 123-139. (doi:10.1007/s10549-007-9632-6)
165. Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP & Grossmann ME 2013 Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. Cancer Prevention Research 6 540-547. (doi:10.1158/1940-6207.CAPR-13-0033)
166. Moller E, Adami HO, Mucci LA, Lundholm C, Bellocco R, Johansson JE, Gronberg H & Balter K 2013 Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes & Control 24 2143-2155. (doi:10.1007/s10552-013-0291-0)
167. Mondul AM, Clipp SL, Helzlsouer KJ & Platz EA 2010 Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes & Control 21 61-68. (doi:10.1007/ s10552-009-9434-8)
168. Mondul AM, Weinstein SJ, Virtamo J & Albanes D 2011 Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes & Control 22 1545-1552. (doi:10.1007/s10552-011-9831-7)
169. Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ et al. 2014 Influence of age on incident diabetes and cardiovascular disease among prostate cancer survivors receiving androgen deprivation therapy. Journal of Urology 193 1226-1231. (doi:10.1016/j.juro.2014.11.006)
170. Mostaghel EA, Solomon KR, Pelton K, Freeman MR & Montgomery RB 2012 Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLo S ONE 7 e30062. (doi:10.1371/journal.pone.0030062)
171. Moyer VA & U.S. Preventative Services Task Force 2012 Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 157 120-134. (doi:10.7326/0003-4819-157-2-201207170-00459)
172. Munsell MF, Sprague BL, Berry DA, Chisholm G & Trentham-Dietz A 2014 Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiologic Reviews 36 114-136. (doi:10.1093/epirev/mxt010)
173. Murtola TJ, Tammela TL, Lahtela J & Auvinen A 2008 Antidiabetic medication and prostate cancer risk: a population-based case-control study. American Journal of Epidemiology 168 925-931. (doi:10.1093/aje/ kwn190)
174. Murtola TJ, Visvanathan K, Artama M, Vainio H & Pukkala E 2014 Statin use and breast cancer survival: a nationwide cohort study from Finland. PLo S ONE 9 e110231. (doi:10.1371/journal.pone.0110231)
175. Narayanan BA, Narayanan NK, Pittman B & Reddy BS 2004 Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal antiinflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clinical Cancer Research 10 7727-7737. (doi:10.1158/1078-0432. CCR-04-0732)
176. Narayanan BA, Narayanan NK, Pttman B & Reddy BS 2006 Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 66 257-265. (doi:10.1002/pros.20331)
177. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, Mc Guire DK, Grundy SM et al. 2013 Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 21 E439-E447. (doi:10.1002/ oby.20135)
178. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V et al. 2013 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342 1094-1098. (doi:10.1126/science.1241908)
179. Nielsen SF, Nordestgaard BG & Bojesen SE 2012 Statin use and reduced cancer-related mortality. New England Journal of Medicine 367 1792-1802. (doi:10.1056/NEJMoa1201735)
180. Niraula S, Ocana A, Ennis M & Goodwin PJ 2012 Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Research and Treatment 134 769-781. (doi:10.1007/s10549-012-2073-x)
181. Nogueira LM, Dunlap SM, Ford NA & Hursting SD 2012 Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocrine-Related Cancer 19 57-68. (doi:10.1530/ERC-11-0213)
182. Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC & Hursting SD 2008 Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutrition and Cancer 60 534-541. (doi:10.1080/01635580801966195)
183. Ogden CL, Carroll MD, Kit BK & Flegal KM 2014 Prevalence of childhood and adult obesity in the United States, 2011-2012. Journal of the American Medical Association 311 806-814. (doi:10.1001/jama. 2014.732)
184. Pape-Ansorge KA, Grande JP, Christensen TA, Maihle NJ & Cleary MP 2002 Effect of moderate caloric restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-Neu female mice. Nutrition and Cancer 44 162-168. (doi:10.1207/S15327914NC4402-07)
185. Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R & Mucci LA 2013 Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Annals of Oncology 24 1427-1434. (doi:10.1093/annonc/mdt077)
186. Patel T, Hruby G, Badani K, Abate-Shen C & Mc Kiernan JM 2010 Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76 1240-1244. (doi:10.1016/j.urology. 2010.03.059)
187. de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, Gomez-Acebo I, Pollan M & Llorca J 2015 Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment 149 525-536. (doi:10.1007/s10549-015-3267-9)
188. Pelton K, Freeman MR & Solomon KR 2012 Cholesterol and prostate cancer. Current Opinion in Pharmacology 12 751-759. (doi:10.1016/ j.coph.2012.07.006)
189. Phipps AI, Malone KE, Porter PL, Daling JR & Li CI 2008 Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 17 2078-2086. (doi:10.1158/1055-9965.EPI-08-0206)
190. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, Tjonneland A, Severinsen MT, Overvad K, ohrmann S et al. 2008 Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiology, Biomarkers & Prevention 17 3252-3261. (doi:10.1158/1055-9965.EPI-08-0609)
191. Platz EA, Clinton SK & Giovannucci E 2008 Association between plasma cholesterol and prostate cancer in the PSA era. International Journal of Cancer 123 1693-1698. (doi:10.1002/ijc.23715)
192. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr & Kristal AR 2009 Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention 18 2807-2813. (doi:10.1158/ 1055-9965.EPI-09-0472)
193. Pou KM, Massaro JM, Hoffmann U, Lieb K, Vasan RS, O'Donnell CJ & Fox CS 2009 Patterns of abdominal fat distribution: the Framingham Heart Study. Diabetes Care 32 481-485. (doi:10.2337/dc08-1359)
194. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO & Sorensen HT 2014 Metformin use and prostate cancer risk. European Urology 66 1012-1020. (doi:10.1016/j.eururo. 2014.04.027)
195. Renehan AG 2009 Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncology 10 640-641. (doi:10.1016/S1470-2045 (09)70170-6)
196. Renehan AG, Tyson M, Egger M, Heller RF & Zwahlen M 2008 Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 569-578. (doi:10.1016/ S0140-6736(08)60269-X)
197. Ridker PM & Cook NR 2013 Statins: new American guidelines for prevention of cardiovascular disease. Lancet 382 1762-1765. (doi:10.1016/S0140-6736(13)62388-0)
198. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H & Isola J 2002 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research 62 632-635.
199. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A & Thun MJ 2001 Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiology, Biomarkers & Prevention 10 345-353.
200. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, Mc Cullough ML, Patel AV, Thun MJ & Calle EE 2007 Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers & Prevention 16 63-69. (doi:10.1158/ 1055-9965.EPI-06-0754)
201. Rodvold KA, Rushing DA & Tewksbury DA 1988 Doxorubicin clearance in the obese. Journal of Clinical Oncology 6 1321-1327.
202. Rogozina OP, Nkhata KJ, Nagle EJ, Grande JP & Cleary MP 2013 The protective effect of intermittent calorie restriction on mammary tumorigenesis is not compromised by consumption of a high fat diet during refeeding. Breast Cancer Research and Treatment 138 395-406. (doi:10.1007/s10549-013-2464-7)
203. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P & Magnusson C 2006 Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 15 2482-2488. (doi:10.1158/1055-9965.EPI-06-0489)
204. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D & Force USPST 2007 Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S Preventive Services Task Force. Annals of Internal Medicine 146 376-389. (doi:10.7326/0003-4819-146-5-200703060-00010)
205. Roy M, Kung HJ & Ghosh PM 2011 Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. American Journal of Cancer Research 1 542-561.
206. Rundle AG & Neugut AI 2009 Modeling the effects of obesity and weight gain on PSA velocity. Prostate 69 1573-1578. (doi:10.1002/pros.21005)
207. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P & Moul JW 2007 Relationship between body mass index and prostate cancer screening in the United States. Journal of Urology 177 493-498. (doi:10.1016/ j.juro.2006.09.059)
208. Schmitz KH, Neuhouser ML, Agurs-Collins T, Zanetti KA, Cadmus-Bertram L, Dean LT & Drake BF 2013 Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. Journal of the National Cancer Institute 105 1344-1354. (doi:10.1093/jnci/djt223)
209. Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H & Messing E 2013 Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU International 111 E71-E77. (doi:10.1111/j.1464-410X.2012.11527.x)
210. Shafique K, Mc Loone P, Qureshi K, Leung H, Hart C & Morrison DS 2012 Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up. BMC Cancer 12 25. (doi:10.1186/1471-2407-12-25)
211. Siegel RL, Miller KD & Jemal A 2015 Cancer statistics, 2015. CA: A Cancer Journal for Clinicians 65 5-29. (doi:10.3322/caac.21254)
212. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, arlsson B et al. 2007 Effects of bariatric surgery on mortality in Swedish obese subjects. New England Journal of Medicine 357 741-752. (doi:10.1056/NEJMoa066254)
213. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, ahlgren S et al. 2009 Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncology 10 653-662. (doi:10.1016/S1470-2045(09)70159-7)
214. Smith MR 2007 Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clinical Cancer Research 13 241-245. (doi:10.1158/1078-0432.CCR-06-2086)
215. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr et al. 2012 Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118 5937-5946. (doi:10.1002/cncr. 27527)
216. Srokowski TP, Fang S, Hortobagyi GN & Giordano SH 2009 Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. Journal of Clinical Oncology 27 2170-2176. (doi:10.1200/JCO.2008.17.5935)
217. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, Bahalim AN, Mc Intire RK, Gutierrez HR, owan M et al. 2012 National, regional, and global trends in adult overweight and obesity prevalences. Population Health Metrics 10 22. (doi:10.1186/1478-7954-10-22)
218. Subbaramaiah K, Norton L, Gerald W & Dannenberg AJ 2002 Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. Journal of Biological Chemistry 277 18649-18657. (doi:10.1074/jbc.M111415200)
219. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA & Dannenberg AJ 2012 Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discovery 2 356-365. (doi:10.1158/2159-8290.CD-11-0241)
220. Suissa S & Azoulay L 2012 Metformin and the Risk of Cancer: Time-related biases in observational studies. Diabetes Care 35 2665-2673. (doi:10.2337/dc12-0788)
221. Sundaram S, Freemerman AJ, Johnson AR, Milner JJ, Mc Naughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA et al. 2013 Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Research and Treatment 142 489-503. (doi:10.1007/s10549-013-2741-5)
222. Sundaram S, Le TL, Essaid L, Freemerman AJ, Huang MJ, Galanko JA, Mc Naughton KK, Bendt KM, Darr DB, Troester MA et al. 2014a Weight loss reversed obesity-induced HGF/c-Met pathway and basal-like breast cancer progression. Frontiers in Oncology 4 175. (doi:10.3389/fonc.2014. 00175)
223. Sundaram S, Freemerman AJ, Galanko JA, Mc Naughton KK, Bendt KM, Darr DB, Troester MA & Makowski L 2014b Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice. PLo S ONE 9 e111394. (doi:10.1371/ journal.pone.0111394)
224. Suzuki R, Orsini N, Saji S, Key TJ & Wolk A 2009 Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status - a meta-analysis. International Journal of Cancer 124 698-712. (doi:10.1002/ijc.23943)
225. Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ & Ma CX 2014 Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Research and Treatment 146 189-197. (doi:10.1007/s10549-014-3002-y)
226. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ & Neugut AI 2004 Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Journal of the American Medical Association 291 2433-2440. (doi:10.1001/jama.291.20.2433)
227. Thomas JA II, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M & Freedland SJ 2010 Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer and Prostatic Diseases 13 350-355. (doi:10.1038/pcan.2010.24)
228. Thompson HJ & Mc Tiernan A 2011 Weight cycling and cancer: weighing the evidence of intermittent caloric restriction and cancer risk. Cancer Prevention Research 4 1736-1742. (doi:10.1158/1940-6207. CAPR-11-0133)
229. Thompson MD, Grubbs CJ, Bode AM, Reid JM, Mc Govern R, Bernard PS, Stijleman IJ, Green JE, Bennett C, Juliana MM et al. 2015 Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. Cancer Prevention Research 8 231-239. (doi:10.1158/ 1940-6207.CAPR-14-0181-T)
230. Togawa K, Ma H, Sullivan-Halley J, Neuhouser ML, Imayama I, Baumgartner KB, Smith AW, Alfano CM, Mc Tiernan A, allard-Barbash R et al. 2014 Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. Breast Cancer Research 16 414. (doi:10.1186/s13058-014-0414-x)
231. Tsai H, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Yood MU, Smith MR & Potosky AL 2014 Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. Journal of Urology 193 1956-1962. (doi:10.1016/j.juro.2014.12.027)
232. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, zoulaki I et al. 2014 Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37 2522-2532. (doi:10.2337/dc14-0584)
233. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE & Ioannidis JP 2015a Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350 g7607. (doi:10.1136/bmj.g7607)
234. Tsilidis KK, Allen NE, Appleby PN, Rohrmann S, Nothlings U, Arriola L, Gunter MJ, Chajes V, Rinaldi S, omieu I et al. 2015b Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. International Journal of Cancer 136 372-381. (doi:10.1002/ijc.28989)
235. Undela K, Srikanth V & Bansal D 2012 Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Research and Treatment 135 261-269. (doi:10.1007/s10549-012-2154-x)
236. Vazquez-Martin A, Oliveras-Ferraros C & Menendez JA 2009 The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8 88-96. (doi:10.4161/cc.8.1.7499)
237. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Adriole GL & Freedland SJ 2014 Aspirin, NSAID and risk of prostate cancer: results from the REDUCE study. Clinical Cancer Research 15 756-762. (doi:10.1158/1078-0432)
238. Vrieling A, Buck K, Kaaks R & Chang-Claude J 2010 Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Research and Treatment 123 641-649. (doi:10.1007/s10549-010-1116-4)
239. Wang D & Dubois RN 2010 Eicosanoids and cancer. Nature Reviews. Cancer 10 181-193. (doi:10.1038/nrc2809)
240. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS et al. 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 209-221. (doi:10.1016/S1535-6108(03)00215-0)
241. Wang X, Lin YW, Wu J, Zhu Y, Xu XL, Xu X, Liang Z, Hu ZH, Li SQ, Zheng XY et al. 2014 Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World Journal of Surgical Oncology 12 304. (doi:10.1186/1477-7819-12-304)
242. Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL & Freedland SJ 2011 Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. Prostate Cancer and Prostatic Diseases 14 361-366. (doi:10.1038/pcan. 2011.42)
243. Woditschka S, Haag JD, Mau B, Lubet RA & Gould MN 2008 Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. Breast Cancer Research 10 R18. (doi:10.1186/bcr1864)
244. Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R & Wockel A 2012 Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Research and Treatment 131 925-931. (doi:10.1007/s10549-011-1874-7)
245. World Cancer Research Fund/American Institute for Cancer Research 2007 Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR.
246. Wright JL & Stanford JL 2009 Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes & Control 20 1617-1622. (doi:10.1007/s10552-009-9407-y)
247. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A & Leitzmann MF 2007 Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109 675-684. (doi:10.1002/cncr. 22443)
248. Wu C, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL & Freedland SJ 2013 Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. BJU International 111 E310-E318. (doi:10.1111/j.1464-410X.2012. 11687.x)
249. Xu H, Hu MB, Bai PD, Zhu WH, Ding Q & Jiang HW 2014 Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression? International Urology and Nephrology 46 2327-2334. (doi:10.1007/s11255-014-0823-x)
250. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, ox A et al. 2011 Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. Journal of the National Cancer Institute 103 250-263. (doi:10.1093/jnci/djq526)
251. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T & Wada S 2000 Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89 589-596. (doi:10.1002/1097-0142(20000801)89:3!589::AID-CNCR14O3.0.CO;2-C)
252. Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H, Gao X & He X 2014a Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLo S ONE 9 e116327. (doi:10.1371/journal.pone.0116327)
253. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S & Azoulay L 2014b USe of statins and the risk of death in patients with prostate cancer. Journal of Clinical Oncology 32 5-11. (doi:10.1200/JCO.2013. 49.4757)
254. Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, Qiu J & Lei H 2012 Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetologica 49 S235-S246. (doi:10.1007/s00592-012-0439-5)
255. Zhang P, Li H, Tan X, Chen L & Wang S 2013 Association of metformin use with cancer incidence and mortality: a metaanalysis. Cancer Epidemiology 37 207-218. (doi:10.1016/j.canep. 2012.12.009)
256. Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J, Liu C & Guo H 2015 Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. Oncology Letters 9 1307-1312. (doi:10.3892/ol.2014. 2841)
257. Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1996 Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 5739-5742. (doi:10.1210/endo.137.12. 8940410)
258. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N et al. 2001 Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 108 1167-1174. (doi:10.1172/JCI13505)
259. Zhuang L, Lin J, Lu ML, Solomon KR & Freeman MR 2002 Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Research 62 2227-2231.